The findings shows that height has an important impact on the mortality from certain common diseases, irrespective of body fat mass and other modulating factors, researchers said.
Previous studies have shown that tall people, in comparison to short people, have a lower risk of cardiovascular disease and type 2 diabetes but have a higher cancer risk.
"Epidemiological data show that per 6.5 centimetres in height the risk of cardiovascular mortality decreases by six per cent, but cancer mortality, by contrast, increases by four per cent," said Matthias Schulze from the German Institute of Human Nutrition.
Thus, already in utero, lifelong programming might take place that until now has mainly been established for the insulin-like growth factor (IGF) 1 and 2 and the IGF-1/2 system.
Among other consequences, activation of this system causes the body to become more sensitive to insulin action, thus positively influencing the lipid metabolism.
"Accordingly, our new data show that tall people are more sensitive to insulin and have lower fat content in the liver, which may explain their lower risk for cardiovascular disease and type 2 diabetes," said Norbert Stefan from the German Centre for Diabetes Research.
However, this activation of the IGF-1/2 system and other signalling pathways may be related to an increased risk of certain cancers, especially breast cancer, colon cancer, and melanoma because cell growth is permanently activated, researchers said.
The result is an inverse association with the risk of cardiovascular disease and type 2 diabetes, but a positive association with the risk of cancer.
Researchers advocate considering the factor growth and adult height more than hitherto in the prevention of major diseases.
The findings were published in the journal The Lancet Diabetes and Endocrinology.
